Eutropics Pharmaceuticals, Inc. is working on development and discovery of clinical tools to aid in the diagnosis and treatment of cancer. Organized around an effort to displace current treatment paradigms by developing novel therapies tailored to an individual's cancer profile that would be identified by the firm's proprietary diagnostic technology, the approach is designed to illuminate the path to more effective treatments and reduce unnecessary suffering. The company's technology platform, PraediCare Dx, delivers in vitro diagnostic assays. As a start-up, the firm came out of Harvard Medical School, Dana Farber Cancer Institute and MIT and received support from the states Life Sciences Center
